Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.
- Collette, S.
- Collette, L.
- Budiharto, T.
- Horiot, J.C.
- Poortmans, P.M.P.
- Struikmans, H.
- Bogaert, W. van den
- Fourquet, A.
- Jager, J.J.
- Hoogenraad, W.J.
- Mueller, R.P.
- Kurtz, J.
- Morgan, D.A.
- Dubois, J.B.
- Salamon, E.
- Mirimanoff, R.O.
- Bolla, M.
- Hulst, M. van der
- Warlam-Rodenhuis, C.C.
- Bartelink, H.
DOIAbstract
Contains fulltext : 71420.pdf (publisher's version ) (Closed access)The EORTC 22881-10882 trial in 5178 conservatively treated early breast cancer patients showed that a 16 Gy boost dose significantly improved local control, but increased the risk of breast fibrosis. To investigate predictors for the long-term risk of fibrosis, Cox regression models of the time to moderate or severe fibrosis were developed on a random set of 1797 patients with and 1827 patients without a boost, and validated in the remaining set. The median follow-up was 10.7 years. The risk of fibrosis significantly increased (P6 MV photons. The c-index was around 0.62. Nomograms with these factors are proposed to forecast the long-term risk of moderate o...
Add to ORKG